Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome: A Preliminary Study

JAMA

Volumn 290, Issue 24, 2003, Pages 3222-3228

  Loutfy, Mona R ^a   Blatt, Lawrence M ^c   Siminovitch, Katharine A ^b   Ward, Sarah ^b   Wolff, Bryan ^a   Lho, Hyoung ^a   Pham, Dieu H ^a   Deif, Hassan ^a   LaMere, Elizabeth A ^a   Chang, Margaret ^a   Kain, Kevin C ^b   Farcas, Gabriella A ^b   Ferguson, Patti ^a   Latchford, Mary ^a   Levy, Gary ^b   Dennis, James W ^b   Lai, Enoch K Y ^a   Fish, Eleanor N ^b,d  

^a NORTH YORK GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Intermune Corp   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONSENSUS INTERFERON; CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DRUG EFFICACY; ENDOTRACHEAL INTUBATION; ENZYME ASSAY; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; INTENSIVE CARE UNIT; LYMPHOCYTOPENIA; MALE; MYALGIA; NEUTROPENIA; OPEN STUDY; OXYGEN SATURATION; OXYGEN THERAPY; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 0348136783     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.24.3222     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Updated interim US case definition of severe acute respiratory syndrome (SARS). Available at: http://www.cdc.gov/ncidod/sars/casedefinition.htm. Accessed November 18, 2003.
2. World Health Organization. Revised case definition of SARS. Available at: http://www.who.int/csr/sars/casedefinition/en. Accessed November 18, 2003.
3. World Health Organization. Cumulative number of reported probable cases of severe acute respiratory syndrome (SARS). Available at: http://www.who.int/csr/sars/country/table2003_09_23/en. Accessed November 18, 2003.
4. Oba Y. The use of corticosteroids in SARS. N Engl J Med. 2003;348:2034.
5. So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet. 2003;361:1615-1617.
6. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801-2809.
7. Wu W, Wang J, Liu P, et al. A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China. Chin Med J (Engl). 2003;116:811-818.
8. Brierley M, Fish EN. IFN-α/β-receptor interactions to biological outcomes: understanding the circuitry. J Interferon Cytokine Res. 2002;22:835-845.
9. Samuel CE. Antiviral action of IFNs. Clin Microbiol Rev. 2001;14:778-809.
10. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 2001;12:143-156
11. Biron CA. IFNs-α and -β as immune regulators - a new look. Immunity. 2001;14:661-664.
12. Cornberg M, Wedemeyer H, Manns MP. Hepatitis C: therapeutic perspectives. Forum (Genova). 2001;11:154-162.
13. Nguyen MH, Wright TL. Therapeutic advances in the management of hepatitis B and hepatitis C. Curr Opin Infect Dis. 2001;14:593-601.
14. Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DA. Intranasal IFN as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother. 1983;24:713-715.
15. Tyrrell DA. The efficacy and tolerance of intranasal IFNs: studies at the Common Cold Unit. J Antimicrob Chemother. 1986;18(suppl B):153-156.
16. Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of experimental coronavirus colds with intranasal alpha-2b IFN. J Infect Dis. 1986;154:443-447.
17. Sperber SJ, Hayden FG. Comparative susceptibility of respiratory viruses to recombinant IFNS-alpha 2b and -beta. J Interferon Res. 1989;9:285-293.
18. Cinatl J, Morgnestern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human IFNs. Lancet. 2003;362:293-294.
19. Alton K, Stabinsky Y, Richards R, et al. Production, characterization and biological effects of recombinant DNA derived humans IFN-α and IFN-γ analogs. In: De Maeyer E, Schellekens H, eds. The Biology of the IFN System 1983. Amsterdam, the Netherlands: Elsevier Science; 1983:119-128.
20. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic IFN-alpha species, consensus IFN. J Interferon Cytokine Res. 1996;16:489-499.
21. Melian EB, Plosker GL. IFN alfacon-1: a review of pharmacology and therapeutic efficacy in the treatment of chronic hepatiti C. Drugs. 2001;61:1661-1691.
22. Friis RH, Stellars TA. Epidemiology for Public Health Practice. Gaithersburg, Md: Aspen; 1996.
23. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-1772.
24. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of IFN alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273-1279.
25. Fujimori K, Mochida S, Matsui A, et al. Possible mechanisms of elevation of serum transaminase levels during IFN-beta therapy in chronic hepatitis C patients. J Gastroenterol. 2002;37:40-46.
26. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986-1994.
27. Avendano M, Derkach P, Swan S. Clinical course and management of SARS in health care workers in Toronto: a case series. CMAJ. 2003;168:1649-1660.
28. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995-2005.
29. Pockros PJ, Reindollar R, McHutchinson J, et al. The safety and tolerability of daily IFN alfacon-1 plus ribavirin in the treatment of naive chronic hepatitis C patients. J Viral Hepat. 2003;10:55-60.
30. Cotler SJ, Layden JE, Neumann AU, Jensen DM. First phase hepatitis C viral kinetics in previous nonresponder patients. J Viral Hepat. 2003;10:43-49.